Replies to post #383934 on Elite Pharmaceuticals Inc (ELTP)

[Pharma Sleuth]

Fortunately or unfortunately depending on how you look at it, the company has mostly taken the position to let the numbers speak for themselves and they are truly fantastic for a company at this market cap. Closing in on 40m in revenues, 40m cap. Earnings, low PE and heavy continuous investment into R&D with drug trials, development etc...

Also some of the biggest most well known drugs on the market which is obviously part of their focus.

Also keep in mind most of these guys if not all aren't even in this country.

[jour_trader]

Here’s a few solid ideas to start (not in prioritized order):
- Work with the management to decrease outstanding share count.
- Continue to increase profitability (potentially current strategic state)
- Complete separation from Elite and CEO’s company, Mikah
- Separate CEO & Chairman roles
- Uplist off OTC
- Implement a small recurring buyback that swallows up more than the annual dilution (going back to first point)
- Get some of those big needle movers filed so investors can see the BE study results, products and total market so actual analysis can be done on the pipeline.
- Hire a CFO that sticks around longer than a year.
- Submit financials without need for amendments.
- Build credibility with shareholders by doing what mgmt says company will do (much better than history, still long road ahead). A crushed stock from credibility being hammered is incredibly hard to fix. Financial results will speak for themselves when Elite gets larger products filed, approved & launched. It’s unlikely this will take place in 2024 so you’re looking 2-3 years out due to no big BE studies reported on yet and the time it takes from BE to FDA filing, approval (no CRLs despite Elite having a history of them) and launch.